These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30404086)

  • 21. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.
    Yang Y; Wang X; Wang C; Qin Y
    Int J Hematol; 2015 Feb; 101(2):165-72. PubMed ID: 25540065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
    Usseglio F; Beaufils N; Calleja A; Raynaud S; Gabert J
    J Mol Diagn; 2017 Jan; 19(1):92-98. PubMed ID: 27855276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
    Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
    Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Relationship between Calreticulin Gene Mutation and JAK2/MPL Negative Myeloproliferative Neoplasms].
    Dong L; Shen XL; Wei W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1532-4. PubMed ID: 26524072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
    Rumi E; Cazzola M
    Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
    Mela Osorio MJ; Ferrari L; Goette NP; Gutierrez MI; Glembotsky AC; Maldonado AC; Lev PR; Alvarez C; Korin L; Marta RF; Molinas FC; Heller PG
    Eur J Haematol; 2016 Apr; 96(4):435-42. PubMed ID: 26119186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
    Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.
    Trifa AP; Popp RA; Cucuianu A; Bănescu C; Tevet M; Martin B; Murat M; Vesa SC; Dima D; Cândea M; Militaru MS; Pop IV
    Br J Haematol; 2015 Jan; 168(1):151-3. PubMed ID: 25103987
    [No Abstract]   [Full Text] [Related]  

  • 31. A Rare Case of Essential Thrombocythemia with Coexisting
    Jang MA; Seo MY; Choi KJ; Hong DS
    J Korean Med Sci; 2020 Jun; 35(23):e168. PubMed ID: 32537949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
    Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
    Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calreticulin mutations and long-term survival in essential thrombocythemia.
    Tefferi A; Wassie EA; Lasho TL; Finke C; Belachew AA; Ketterling RP; Hanson CA; Pardanani A; Gangat N; Wolanskyj AP
    Leukemia; 2014 Dec; 28(12):2300-3. PubMed ID: 24791854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High resolution melting analysis: a rapid and accurate method to detect CALR mutations.
    Bilbao-Sieyro C; Santana G; Moreno M; Torres L; Santana-Lopez G; Rodriguez-Medina C; Perera M; Bellosillo B; de la Iglesia S; Molero T; Gomez-Casares MT
    PLoS One; 2014; 9(7):e103511. PubMed ID: 25068507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].
    Ben Said M; Gandrille S; Fischer AM; Darnige L
    Pathol Biol (Paris); 2015 Jun; 63(3):117-21. PubMed ID: 25840625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
    Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
    BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
    Tefferi A; Lasho TL; Finke CM; Knudson RA; Ketterling R; Hanson CH; Maffioli M; Caramazza D; Passamonti F; Pardanani A
    Leukemia; 2014 Jul; 28(7):1472-7. PubMed ID: 24402162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombotic risk correlates with mutational status in true essential thrombocythemia.
    Bertozzi I; Peroni E; Coltro G; Bogoni G; Cosi E; Santarossa C; Fabris F; Randi ML
    Eur J Clin Invest; 2016 Aug; 46(8):683-9. PubMed ID: 27271054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases].
    Li ZL; Gao L; Zhang H; Zhang CX; Chen YR; Huang FZ; Gong M; Gao YY; Tang Y; Ma YG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1122-1128. PubMed ID: 30111418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria.
    Kvasnicka HM
    Rinsho Ketsueki; 2019; 60(9):1166-1175. PubMed ID: 31597840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.